The startup develops cerebrovascular protective therapies that utilize a neuroprotective molecule to mitigate oxidative stress in the neurological and cardiovascular systems. This therapy effectively prevents damage caused by reperfusion after a stroke, enabling patients to recover without disabilities.
Funding
$2.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Despite advancements in acute ischemic stroke (AIS) treatment, including mechanical thrombectomy (MT), a significant proportion of patients still experience long-term disability due to inadequate brain microcirculation and reperfusion following the procedure. Current therapies often fail to fully restore functional independence, leading to increased healthcare costs and reduced quality of life for stroke survivors.
Solution
FreeOx Biotech is developing cerebrovascular protective therapeutics, with its lead asset, Ox-01, a carefully engineered formulation of Uric Acid (UA), designed as an emergency adjunct therapy to Mechanical Thrombectomy (MT) for the treatment of Acute Ischemic Stroke (AIS). Ox-01 is administered via a 90-minute IV infusion before or during MT to enhance brain microcirculation and boost penumbra reperfusion through a multi-modal mechanism of action. By improving microcirculation, Ox-01 aims to increase the number of patients achieving functional independence post-stroke, addressing a critical unmet need in stroke care. FreeOx Biotech also has Lip-Ox, a proprietary liposomal formulation technology based on Uric Acid, which has the unique ability to induce superior drug characteristics (e.g., cross the blood-brain barrier), making it a versatile multi-product/multi indication platform for our future.
Target Audience
The primary target audience includes stroke neurologists, interventional neuroradiologists, and hospitals specializing in acute stroke care, seeking to improve patient outcomes following mechanical thrombectomy for acute ischemic stroke.
Features
- Ox-01: Pharmaceutical-grade Uric Acid formulation designed for IV infusion during mechanical thrombectomy
- Enhances brain microcirculation and boosts penumbra reperfusion
- Demonstrated a 19% increase in patients achieving good outcomes (independent living) in a Phase IIb clinical trial
- Lip-Ox: Proprietary liposomal formulation technology based on Uric Acid
- Lip-Ox is designed to customize a sustained release mechanism and a shift to simple IV injection, both ideal for non-emergency indications in neurology.
- Granted use patent covering Uric Acid with MT in the US, South Korea and Australia
- Intellectual protection covers proprietary API synthesis GMP process and pharmaceutical product formulation process